When.com Web Search

  1. Ads

    related to: contraindications to prevozi lights therapies for diabetes

Search results

  1. Results From The WOW.Com Content Network
  2. Dulaglutide - Wikipedia

    en.wikipedia.org/wiki/Dulaglutide

    Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

  3. Albiglutide - Wikipedia

    en.wikipedia.org/wiki/Albiglutide

    Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. [ 2 ]

  4. Semaglutide - Wikipedia

    en.wikipedia.org/wiki/Semaglutide

    Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [ 23 ] [ 24 ] [ 25 ] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain .

  5. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.

  6. Bright light at night from phones, cable box can boost risk ...

    www.aol.com/bright-light-night-phones-cable...

    Researchers found exposure to brighter light at night predicted higher risk of type 2 diabetes across an average of eight years of follow-up.

  7. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity in the ...